EUVIMEDEUVIMED entdecken
Crossref

Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma

Keying Zhu, Shimin Tang, Donghui Pan, Xinyu Wang, Yuping Xu, Junjie Yan, Lizhen Wang, Chongyang Chen, Min Yang iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07107-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Keying Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Adenocarcinoma of Lung, Antigens, CD, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Low-dose CT (LDCT) screening effectively reduces lung adenocarcinoma (LUAD) mortality. However, accurately evaluating the malignant potential of indeterminate lung nodules remains a challenge. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6), a potential biomarker for distinguishing benign pulmonary nodules from LUAD, may be leveraged for noninvasive positron emission tomography (PET) imaging to aid LUAD diagnosis. METHODS: This study utilized mRNA, protein, and survival datasets of LUAD patients, along with an animal model of malignant pulmonary nodules, to investigate CEACAM6 expression specificity and its correlation with LUAD. Targeting ligands for CEACAM6 were designed using the Rosetta platform, labeled with [68Ga]Ga, and screened through high-throughput PET imaging to identify the optimal tracer. RESULTS: CEACAM6 was found to be specifically overexpressed in LUAD and was significantly associated with poor prognosis and disease progression. In vivo, [68Ga]Ga-NODA-P3 demonstrated high specificity for delineating CEACAM6-positive A549 xenografts, a LUAD model, via PET imaging, achieving a highest target-to-background ratio of 7.68 ± 0.44. Region of interest (ROI) analysis showed significantly higher tracer uptake in A549 xenografts compared to CEACAM6-negative Huh7 xenografts (a hepatocellular carcinoma model) at 30 min post-injection (1.81 ± 0.10%ID/g vs. 0.54 ± 0.06%ID/g). Pre-treatment with an excess of unlabeled NODA-P3 significantly reduced tumor uptake to 0.52 ± 0.07%ID/g. CONCLUSION: These preclinical findings indicate that [68Ga]Ga-NODA-P3 is a candidate radiotracer for the non-invasive visualization of CEACAM6-positive LUAD, demonstrating favorable imaging contrast. Although the current tumor uptake limits its immediate clinical application, ongoing optimization efforts are expected to improve its efficacy, enabling earlier and more accurate diagnosis of malignant pulmonary nodules in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Adhesion MoleculesAdenocarcinoma of LungAntigens, CDLung NeoplasmsPositron-Emission TomographyHumansAnimalsGPI-Linked ProteinsMiceFemaleMaleRadioactive TracersNeoplasm StagingCell Line, TumorA549 Cells

Stichwörter der Autor:innen

CEACAM6DiagnosisLUADPositron emission tomography (PET)[68Ga]Ga

Substanzen

CEACAM6 protein, humanCell Adhesion MoleculesGPI-Linked ProteinsAntigens, CDRadioactive Tracers

Autor:innen und Institutionen

  • School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 214063, Wuxi, China.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 214063, Wuxi, China. chenchongyang@jsinm.org.
  • School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. yangmin@jsinm.org.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, 214063, Wuxi, China. yangmin@jsinm.org.

ORCID-Profile: Min Yang

Förderung

  • Natural Science Foundation of Jilin Province

Zitieren

APA

Zhu, K., Tang, S., Pan, D., Wang, X., Xu, Y., Yan, J., Wang, L., Chen, C., & Yang, M. (2025). Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07107-3

Vancouver

Zhu K, Tang S, Pan D, Wang X, Xu Y, Yan J, et al. Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07107-3

BibTeX
@article{Zhu2025,
  author = {Zhu, Keying and Tang, Shimin and Pan, Donghui and Wang, Xinyu and Xu, Yuping and Yan, Junjie and Wang, Lizhen and Chen, Chongyang and Yang, Min},
  title = {Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07107-3}
}
Kostenlos starten →